newsfilter
← Latest News
Earnings Call Transcripts·

Jefferies Global Healthcare Conference in London - PRIME MEDICINE INC

  • Explicit Guidance:

    • Clinical Data Timelines: Aiming for first approval next year (FY2024) for the ex vivo Chronic Granulomatous Disease (CGD) program; guidance to provide "fulsome" clinical data updates for the Wilson disease program in 2027.
    • First Patient Dosing: Expectation to dose the first patient in the Alpha-1 Antitrypsin Deficiency (A1AT) Phase 1-2 study by "end of the year or soon after" (relative to the Sept IND clearance mentioned in the transcript, implying late FY2023/early FY2024).
    • Pipeline Milestones: Anticipation of selecting a drug candidate for Cystic Fibrosis "sometime next year."
    • Financial Strategy: Commitment to pursue "less equity-dilutive" capital sources, including Business Development (BD) deals and monetization of Regulatory Vouchers (e.g., BMS milestones), to fund the company beyond recent raises.
  • Business-Segment Outlook:

    • Wilson Disease: Enrollment expected to be robust due to high patient motivation and a queue of identified patients from a late-2023 observational study; sites confirmed in New Zealand, the U.S., and upcoming sites in Europe. The trial includes multiple sites globally.
    • Alpha-1 Antitrypsin Deficiency (A1AT): Targeting a population of 8,000–10,000 patients on augmentation therapy in the U.S., with a potentially larger pool ex-U.S.; facing competition from multiple developers but maintaining site access.
    • CGD Program: Positioned for regulatory approval next year; currently in the final stages prior to this milestone.
    • Cystic Fibrosis: Progressing toward drug candidate selection next year, representing a future growth lever.
    • Next Indications: Actively evaluating liver indications beyond Wilson and A1AT, targeting populations in the "hundreds of thousands or even millions"; also exploring opportunities driven by potential FDA guidance on personalized gene editing.
  • Market and Competitive Outlook:

    • Competitive Landscape: Acknowledges three companies performing prime editing (Prime Medicine, CRISPR Therapeutics, Tessera) and two performing base editing; notes that competitors like Beam have larger current patient numbers but early-stage data from other firms is insufficient for direct comparison.
    • Differentiation Strategy: Belief that safety profiles (LNP toxicity) and clinical efficacy data over the next 12 months will be the primary differentiators; intends to vigorously enforce IP rights against any infringement regarding the foundational prime editing patent (Cas enzyme + reverse transcriptase + PEG guide).
    • Competitor Catalysts: Monitoring upcoming data from events trials focusing on augmentation therapy for A1AT as a relevant benchmark for the space, despite the different mechanism.
    • Market Size: Planning to expand from tens of thousands of patients (Wilson, A1AT) into larger addressable markets (hundreds of thousands to millions) for future indications.
  • Macro / Industry Outlook:

    • Regulatory Environment: Observing recent FDA guidance on personalized gene editing as a potential catalyst that could alter commercial viability math for indications previously considered smaller or more complex.
    • Clinical Standards: Reliance on radiolabeled copper PET scans (benchmarking against Dr. Sandahl's work) as the standardized metric for efficacy and "genetic cure" definitions (converting to heterozygote status).
  • Strategic Initiatives:

    • Site Expansion: Scaling from initial New Zealand and U.S. sites to a broader European presence for the Wilson disease global study.
    • Patient Identification: Utilizing late-2023 observational data to pre-identify eligible H1069Q mutated patients to streamline enrollment for the Wilson dose-escalation cohorts (targeting initial 9 patients).
    • Capital Allocation: Shifting focus toward non-dilutive capital events (BD, voucher monetization) to sustain operations alongside the upcoming 2024 CGD approval and 2027 Wilson data.
    • Technology Leverage: Planning to leverage the "next-generation" versatility of the prime editing platform for additional indications once the current programs de-risk the technology.
  • Risks and Headwinds to Outlook:

    • Preclinical Translation: Acknowledgment that preclinical data (mouse/monkey) does not always translate perfectly to human dosing; potential for surprises regarding effective dose levels and efficacy windows.
    • Safety Monitoring: Risk of increased liver function tests and inflammatory markers (common with LNPs) occurring early or later than the standard 30-day window; requires monitoring beyond standard windows to differentiate LNP-related toxicity from other causes.
    • Enrollment Nuances: While recruitment is expected to be successful, the actual number of enrolled patients in specific cohorts remains subject to screening success rates despite the observational pre-identification.
    • Competitive Timing: Uncertainty on when competing companies will reach comparable data maturity to allow for clear benchmarking of editing levels and safety profiles.
    • Regulatory Discretion: Final decisions on discontinuing standard of care (SOC) rest with investigator discretion rather than a rigid protocol threshold.
  • Management Tone on the Future:

    • Confidence Level: High confidence regarding the ability to enroll patients for both Wilson and A1AT studies; describes the Wilson trial as having "significant unmet need and high degree of motivation."
    • Strategic Clarity: Expresses strong belief in the safety and precision of the prime editing platform (single-stranded breaks) and the wide therapeutic index established in preclinical studies.
    • Cautious Optimism on Dosing: While expecting to see biological signal at the second dose level due to preclinical data, maintains a measured stance that clinical translation is not guaranteed.
    • Forward-Looking: Frame the next 12 months as a "de-risking" phase leading to the CGD approval and key clinical readouts, with a clear focus on transitioning to commercial viability in larger markets.
  • Miscellaneous:

    • Study Design Specifics: Wilson disease trial includes dose escalation (approx. 3 patients per cohort, initial 9 patients total), with potential for expansion; safety monitoring window is not extended beyond standard periods in the U.S. but allows for staggered geographies.
    • Endpoint Metrics: Primary hope rests on radio-labeled copper PET studies to image improved copper metabolism; secondary endpoints include urinary copper, seroplasmin, and investigator-led SOC discontinuation.
    • Patient Cohorts: Initially targeting compensated liver disease patients (excluding decompensated cirrhotics) to establish safety before expanding to the full Wilson disease population.
    • IP Stance: Asserts exclusive ownership of foundational prime editing IP; indicates readiness to enforce IP rights against other companies using similar permutations of the technology.
Company
PRIME MEDICINE INC
Keywords
PRIME MEDICINE INC